验证弥漫性大B细胞淋巴瘤(DLBCL)的NCCN-IPI:加入β2微球蛋白可产生更准确的GELTAMO-IPI
研究纳入1848例接受化疗/利妥昔单抗治疗的DLBCL患者,验证NCCN-IPI并探索加入高β2微球蛋白、原发结外表现和强烈治疗能否改进指数。NCCN-IPI区分出四组5年总生存率93%、83%、67%、49%,但未能识别真正高危人群;GELTAMO-IPI区分更好,四组5年总生存率93%、79%、66%、39%。
要点
- NCCN-IPI区分四组5年总生存率93%、83%、67%、49%,但未识别真正高危人群。
- 多变量模型显示年龄、LDH、ECOG评分、III-IV期和β2M为独立显著因素。
- GELTAMO-IPI区分四组5年总生存率93%、79%、66%、39%,优于NCCN-IPI。
核心结论
- GELTAMO-IPI比NCCN-IPI更准确,具有统计学和实用优势,更好的区分能识别真正的高危组,且不受原发结外表现或不同强度治疗的影响。
研究设计与样本
- 研究纳入1848例接受化疗/利妥昔单抗治疗的弥漫性大B细胞淋巴瘤(DLBCL)患者,验证NCCN-IPI并探索加入高β2微球蛋白(β2M)、原发结外表现和强烈治疗以开发改进指数。
- 为第二目标将系列分为训练队列和验证队列;在训练队列中多变量模型识别年龄、乳酸脱氢酶、美国东部肿瘤协作组(ECOG)体能状态、III-IV期和β2M为独立显著因素,而NCCN-IPI选择的结外部位、原发结外表现和强烈治疗不显著;这些结果在验证队列中得到确认。
主要发现
- 比较生存曲线,NCCN-IPI比IPI区分更好,分出四个风险组,5年总生存率分别为93%、83%、67%和49%,但未能识别真正的高危人群。
- GELTAMO-IPI共7分,显著分出四个风险组(0分、1-3分、4分或≥5分),患者比例分别为11%、58%、17%和14%,5年总生存率分别为93%、79%、66%和39%。
- 在比较中,GELTAMO-IPI比NCCN-IPI区分更好。
关键数值与推荐
- NCCN-IPI四组5年总生存率:93%、83%、67%、49%。
- GELTAMO-IPI四组(0、1-3、4、≥5分)患者比例:11%、58%、17%、14%;5年总生存率:93%、79%、66%、39%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The study included 1848 diffuse large B-cell lymphoma (DLBCL)patients treated with chemotherapy/rituximab. The aims were to validate the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) and explore the effect of adding high Beta-2 microglobulin (β2M), primary extranodal presentation and intense treatment to the NCCN-IPI variables in order to develop an improved index. Comparing survival curves, NCCN-IPI discriminated better than IPI, separating four risk groups with 5-year overall survival rates of 93%, 83%, 67% and 49%, but failing to identify a true high-risk population. For the second aim the series was split into training and validation cohorts: in the former the multivariate model identified age, lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, Stage III-IV, and β2M as independently significant, whereas the NCCN-IPI-selected extranodal sites, primary extranodal presentation and intense treatments were not. These results were confirmed in the validation cohort. The Grupo Español de Linfomas/Trasplante de Médula ósea (GELTAMO)-IPI developed here, with 7 points, significantly separated four risk groups (0, 1-3, 4 or ≥5 points) with 11%, 58%, 17% and 14% of patients, and 5-year overall survival rates of 93%, 79%, 66% and 39%, respectively. In the comparison GELTAMO IPI discriminated better than the NCCN-IPI. In conclusion, GELTAMO-IPI is more accurate than the NCCN-IPI and has statistical and practical advantages in that the better discrimination identifies an authentic high-risk group and is not influenced by primary extranodal presentation or treatments of different intensity.
引用
- Montalbán C, Díaz-López A, Dlouhy I, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2 -microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017. PMID: 28106247. doi:10.1111/bjh.14489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。